W P Jia, Y Q Bao, H Miao, P Tu, Y Liu, T Yang, W B Wang, B Y Shi, M Liu, W J Hua, N N Hou, Q Zhang, L Hu, S G Pang, J D Liu, G X Wang
Objective: To compare the efficacy and safety of Tonghua Dongbao's insulin aspart injection (Rishulin) and NovoRapid (Novo Nordisk) in the treatment of diabetes. Methods: A 26-week, randomized, open-label, parallel-group, positive control drug and non-inferiority trial was conducted in 23 centers in China. A total of 563 diabetes with poor blood glucose control treated with insulin for at least 3 months before were included. The subjects were randomized(stratified block random method) into those receiving Rishulin or NovoRapid at a ratio of 3∶1...
December 1, 2021: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]